{"id":957243,"date":"2026-05-01T12:33:13","date_gmt":"2026-05-01T16:33:13","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/kalvista-pharmaceuticals-investor-alert-kahn-swick-foti-llc-investigates-adequacy-of-price-and-process-in-proposed-sale-of-kalvista-pharmaceuticals-inc-kalv\/"},"modified":"2026-05-01T12:33:13","modified_gmt":"2026-05-01T16:33:13","slug":"kalvista-pharmaceuticals-investor-alert-kahn-swick-foti-llc-investigates-adequacy-of-price-and-process-in-proposed-sale-of-kalvista-pharmaceuticals-inc-kalv","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/kalvista-pharmaceuticals-investor-alert-kahn-swick-foti-llc-investigates-adequacy-of-price-and-process-in-proposed-sale-of-kalvista-pharmaceuticals-inc-kalv\/","title":{"rendered":"KalVista Pharmaceuticals Investor Alert: Kahn Swick &amp; Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of KalVista Pharmaceuticals, Inc. &#8211; KALV"},"content":{"rendered":"<p>        <!--body {font:normal small Arial,Helvetica,sans-serif;color:#000;background-color:#fff;padding:24px;margin:0;} a img {border:0;} h3 {font-size:medium;color:#000;margin:0 0 1em 0; text-align:center;}-->  <\/p>\n<p>\nKalVista Pharmaceuticals Investor Alert: Kahn Swick &amp; Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of KalVista Pharmaceuticals, Inc. &#8211; KALV<\/p>\n<p>NEW YORK CITY &amp; NEW ORLEANS&#8211;(<a href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;<br \/>\nFormer Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.ksfcounsel.com%2F&amp;esheet=54527121&amp;newsitemid=20260501487041&amp;lan=en-US&amp;anchor=Kahn+Swick+%26amp%3B+Foti&amp;index=1&amp;md5=a9643a7ff9d53c0cd4f5963a95931be5\">Kahn Swick &amp; Foti<\/a>, LLC (\u201cKSF\u201d) are investigating the proposed sale of <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.ksfcounsel.com%2Fcases%2Fnasdaqgm-kalv%2F&amp;esheet=54527121&amp;newsitemid=20260501487041&amp;lan=en-US&amp;anchor=KalVista+Pharmaceuticals&amp;index=2&amp;md5=2ea42c5a4d1e6c4a8b33a99916590a8b\">KalVista Pharmaceuticals<\/a>, Inc. (NasdaqGM: KALV) to Chiesi Group. Under the terms of the proposed transaction, shareholders of KalVista will receive $27.00 in cash for each share of KalVista that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.<\/p>\n<p>\nIf you believe that this transaction undervalues the Company and\/or if you would like to discuss your legal rights regarding the proposed sale, you may, without obligation or cost to you, e-mail or call KSF Managing Partner Lewis S. Kahn (<a rel=\"nofollow\" href=\"mailto:lewis.kahn@ksfcounsel.com\">lewis.kahn@ksfcounsel.com<\/a>) toll free at any time at 855-768-1857, or visit <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.ksfcounsel.com%2Fcases%2Fnasdaqgm-kalv%2F&amp;esheet=54527121&amp;newsitemid=20260501487041&amp;lan=en-US&amp;anchor=https%3A%2F%2Fwww.ksfcounsel.com%2Fcases%2Fnasdaqgm-kalv%2F&amp;index=3&amp;md5=1851c9176a218b2ccf2679f752e28c19\">https:\/\/www.ksfcounsel.com\/cases\/nasdaqgm-kalv\/<\/a> to learn more.<\/p>\n<p><b><i>Please note that the transaction is structured as a tender offer, such that time may be of the essence.<\/i><\/b><\/p>\n<p>\nTo learn more about KSF, whose partners include the Former Louisiana Attorney General, visit <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.ksfcounsel.com&amp;esheet=54527121&amp;newsitemid=20260501487041&amp;lan=en-US&amp;anchor=www.ksfcounsel.com&amp;index=4&amp;md5=23ceefd28a7ab73778bfa016129982cd\">www.ksfcounsel.com<\/a>.<\/p>\n<p>\nCONNECT WITH US: <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.facebook.com%2Fprofile.php%3Fid%3D61575733915628&amp;esheet=54527121&amp;newsitemid=20260501487041&amp;lan=en-US&amp;anchor=Facebook&amp;index=5&amp;md5=88c0e33dc694985c04b5eceb2f06e13f\">Facebook<\/a> || <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.instagram.com%2Fkahn_swick_and_foti%2F&amp;esheet=54527121&amp;newsitemid=20260501487041&amp;lan=en-US&amp;anchor=Instagram&amp;index=6&amp;md5=c781ef785ab98eee09ea2e0115d44db1\">Instagram<\/a> || <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.youtube.com%2F%40kahnswickandfoti&amp;esheet=54527121&amp;newsitemid=20260501487041&amp;lan=en-US&amp;anchor=YouTube&amp;index=7&amp;md5=ff15dbbdff9fa74e2638e44d0314f1ba\">YouTube<\/a> || <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.tiktok.com%2F%40kahn.swick.foti&amp;esheet=54527121&amp;newsitemid=20260501487041&amp;lan=en-US&amp;anchor=TikTok&amp;index=8&amp;md5=4c6a9cf2a330b9d6c1c793afe3907992\">TikTok<\/a> || <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fksfcounsel&amp;esheet=54527121&amp;newsitemid=20260501487041&amp;lan=en-US&amp;anchor=LinkedIn&amp;index=9&amp;md5=1825690194da019fc392821c3b67bca1\">LinkedIn<\/a><\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260501487041r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><span class=\"bwct31415\" \/><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">View source version on businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20260501487041\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20260501487041\/en\/<\/a><\/span><\/p>\n<p>\nKahn Swick &amp; Foti, LLC<br \/>\n<br \/>1100 Poydras St., Suite 960<br \/>\n<br \/>New Orleans, LA 70163<br \/>\n<br \/>Managing Partner<br \/>\n<br \/>Lewis S. Kahn<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:lewis.kahn@ksfcounsel.com\">lewis.kahn@ksfcounsel.com<br \/>\n<\/a><br \/>855-768-1857<\/p>\n<p><b>KEYWORDS:<\/b> Louisiana New York United States North America<\/p>\n<p><b>INDUSTRY KEYWORDS:<\/b> Professional Services Class Action Lawsuit<\/p>\n<p><b>MEDIA:<\/b><\/p>\n<table cellpadding=\"3\" cellspacing=\"3\">\n<tr>\n<td><font face=\"Arial\" size=\"2\"><b>Logo<\/b><\/font><\/td>\n<\/tr>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20260501487041\/en\/2664609\/3\/2025-PR-MA.jpg\" alt=\"Logo\" \/><\/td>\n<\/tr>\n<tr>\n<td><font face=\"Arial\" size=\"2\"><\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"<p>KalVista Pharmaceuticals Investor Alert: Kahn Swick &amp; Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of KalVista Pharmaceuticals, Inc. &#8211; KALV NEW YORK CITY &amp; NEW ORLEANS&#8211;(BUSINESS WIRE)&#8211; Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick &amp; Foti, LLC (\u201cKSF\u201d) are investigating the proposed sale of KalVista Pharmaceuticals, Inc. (NasdaqGM: KALV) to Chiesi Group. Under the terms of the proposed transaction, shareholders of KalVista will receive $27.00 in cash for each share of KalVista that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company. If you believe that this transaction undervalues &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/kalvista-pharmaceuticals-investor-alert-kahn-swick-foti-llc-investigates-adequacy-of-price-and-process-in-proposed-sale-of-kalvista-pharmaceuticals-inc-kalv\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;KalVista Pharmaceuticals Investor Alert: Kahn Swick &amp; Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of KalVista Pharmaceuticals, Inc. &#8211; KALV&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-957243","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>KalVista Pharmaceuticals Investor Alert: Kahn Swick &amp; Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of KalVista Pharmaceuticals, Inc. - KALV - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/kalvista-pharmaceuticals-investor-alert-kahn-swick-foti-llc-investigates-adequacy-of-price-and-process-in-proposed-sale-of-kalvista-pharmaceuticals-inc-kalv\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"KalVista Pharmaceuticals Investor Alert: Kahn Swick &amp; Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of KalVista Pharmaceuticals, Inc. - KALV - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"KalVista Pharmaceuticals Investor Alert: Kahn Swick &amp; Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of KalVista Pharmaceuticals, Inc. &#8211; KALV NEW YORK CITY &amp; NEW ORLEANS&#8211;(BUSINESS WIRE)&#8211; Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick &amp; Foti, LLC (\u201cKSF\u201d) are investigating the proposed sale of KalVista Pharmaceuticals, Inc. (NasdaqGM: KALV) to Chiesi Group. Under the terms of the proposed transaction, shareholders of KalVista will receive $27.00 in cash for each share of KalVista that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company. If you believe that this transaction undervalues &hellip; Continue reading &quot;KalVista Pharmaceuticals Investor Alert: Kahn Swick &amp; Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of KalVista Pharmaceuticals, Inc. &#8211; KALV&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/kalvista-pharmaceuticals-investor-alert-kahn-swick-foti-llc-investigates-adequacy-of-price-and-process-in-proposed-sale-of-kalvista-pharmaceuticals-inc-kalv\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-05-01T16:33:13+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260501487041r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kalvista-pharmaceuticals-investor-alert-kahn-swick-foti-llc-investigates-adequacy-of-price-and-process-in-proposed-sale-of-kalvista-pharmaceuticals-inc-kalv\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kalvista-pharmaceuticals-investor-alert-kahn-swick-foti-llc-investigates-adequacy-of-price-and-process-in-proposed-sale-of-kalvista-pharmaceuticals-inc-kalv\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"KalVista Pharmaceuticals Investor Alert: Kahn Swick &amp; Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of KalVista Pharmaceuticals, Inc. &#8211; KALV\",\"datePublished\":\"2026-05-01T16:33:13+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kalvista-pharmaceuticals-investor-alert-kahn-swick-foti-llc-investigates-adequacy-of-price-and-process-in-proposed-sale-of-kalvista-pharmaceuticals-inc-kalv\\\/\"},\"wordCount\":298,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kalvista-pharmaceuticals-investor-alert-kahn-swick-foti-llc-investigates-adequacy-of-price-and-process-in-proposed-sale-of-kalvista-pharmaceuticals-inc-kalv\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20260501487041r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kalvista-pharmaceuticals-investor-alert-kahn-swick-foti-llc-investigates-adequacy-of-price-and-process-in-proposed-sale-of-kalvista-pharmaceuticals-inc-kalv\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kalvista-pharmaceuticals-investor-alert-kahn-swick-foti-llc-investigates-adequacy-of-price-and-process-in-proposed-sale-of-kalvista-pharmaceuticals-inc-kalv\\\/\",\"name\":\"KalVista Pharmaceuticals Investor Alert: Kahn Swick &amp; Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of KalVista Pharmaceuticals, Inc. - KALV - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kalvista-pharmaceuticals-investor-alert-kahn-swick-foti-llc-investigates-adequacy-of-price-and-process-in-proposed-sale-of-kalvista-pharmaceuticals-inc-kalv\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kalvista-pharmaceuticals-investor-alert-kahn-swick-foti-llc-investigates-adequacy-of-price-and-process-in-proposed-sale-of-kalvista-pharmaceuticals-inc-kalv\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20260501487041r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2026-05-01T16:33:13+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kalvista-pharmaceuticals-investor-alert-kahn-swick-foti-llc-investigates-adequacy-of-price-and-process-in-proposed-sale-of-kalvista-pharmaceuticals-inc-kalv\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kalvista-pharmaceuticals-investor-alert-kahn-swick-foti-llc-investigates-adequacy-of-price-and-process-in-proposed-sale-of-kalvista-pharmaceuticals-inc-kalv\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kalvista-pharmaceuticals-investor-alert-kahn-swick-foti-llc-investigates-adequacy-of-price-and-process-in-proposed-sale-of-kalvista-pharmaceuticals-inc-kalv\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20260501487041r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20260501487041r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kalvista-pharmaceuticals-investor-alert-kahn-swick-foti-llc-investigates-adequacy-of-price-and-process-in-proposed-sale-of-kalvista-pharmaceuticals-inc-kalv\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"KalVista Pharmaceuticals Investor Alert: Kahn Swick &amp; Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of KalVista Pharmaceuticals, Inc. &#8211; KALV\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"KalVista Pharmaceuticals Investor Alert: Kahn Swick &amp; Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of KalVista Pharmaceuticals, Inc. - KALV - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/kalvista-pharmaceuticals-investor-alert-kahn-swick-foti-llc-investigates-adequacy-of-price-and-process-in-proposed-sale-of-kalvista-pharmaceuticals-inc-kalv\/","og_locale":"en_US","og_type":"article","og_title":"KalVista Pharmaceuticals Investor Alert: Kahn Swick &amp; Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of KalVista Pharmaceuticals, Inc. - KALV - Market Newsdesk","og_description":"KalVista Pharmaceuticals Investor Alert: Kahn Swick &amp; Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of KalVista Pharmaceuticals, Inc. &#8211; KALV NEW YORK CITY &amp; NEW ORLEANS&#8211;(BUSINESS WIRE)&#8211; Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick &amp; Foti, LLC (\u201cKSF\u201d) are investigating the proposed sale of KalVista Pharmaceuticals, Inc. (NasdaqGM: KALV) to Chiesi Group. Under the terms of the proposed transaction, shareholders of KalVista will receive $27.00 in cash for each share of KalVista that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company. If you believe that this transaction undervalues &hellip; Continue reading \"KalVista Pharmaceuticals Investor Alert: Kahn Swick &amp; Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of KalVista Pharmaceuticals, Inc. &#8211; KALV\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/kalvista-pharmaceuticals-investor-alert-kahn-swick-foti-llc-investigates-adequacy-of-price-and-process-in-proposed-sale-of-kalvista-pharmaceuticals-inc-kalv\/","og_site_name":"Market Newsdesk","article_published_time":"2026-05-01T16:33:13+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260501487041r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kalvista-pharmaceuticals-investor-alert-kahn-swick-foti-llc-investigates-adequacy-of-price-and-process-in-proposed-sale-of-kalvista-pharmaceuticals-inc-kalv\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kalvista-pharmaceuticals-investor-alert-kahn-swick-foti-llc-investigates-adequacy-of-price-and-process-in-proposed-sale-of-kalvista-pharmaceuticals-inc-kalv\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"KalVista Pharmaceuticals Investor Alert: Kahn Swick &amp; Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of KalVista Pharmaceuticals, Inc. &#8211; KALV","datePublished":"2026-05-01T16:33:13+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kalvista-pharmaceuticals-investor-alert-kahn-swick-foti-llc-investigates-adequacy-of-price-and-process-in-proposed-sale-of-kalvista-pharmaceuticals-inc-kalv\/"},"wordCount":298,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kalvista-pharmaceuticals-investor-alert-kahn-swick-foti-llc-investigates-adequacy-of-price-and-process-in-proposed-sale-of-kalvista-pharmaceuticals-inc-kalv\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260501487041r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kalvista-pharmaceuticals-investor-alert-kahn-swick-foti-llc-investigates-adequacy-of-price-and-process-in-proposed-sale-of-kalvista-pharmaceuticals-inc-kalv\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/kalvista-pharmaceuticals-investor-alert-kahn-swick-foti-llc-investigates-adequacy-of-price-and-process-in-proposed-sale-of-kalvista-pharmaceuticals-inc-kalv\/","name":"KalVista Pharmaceuticals Investor Alert: Kahn Swick &amp; Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of KalVista Pharmaceuticals, Inc. - KALV - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kalvista-pharmaceuticals-investor-alert-kahn-swick-foti-llc-investigates-adequacy-of-price-and-process-in-proposed-sale-of-kalvista-pharmaceuticals-inc-kalv\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kalvista-pharmaceuticals-investor-alert-kahn-swick-foti-llc-investigates-adequacy-of-price-and-process-in-proposed-sale-of-kalvista-pharmaceuticals-inc-kalv\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260501487041r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","datePublished":"2026-05-01T16:33:13+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kalvista-pharmaceuticals-investor-alert-kahn-swick-foti-llc-investigates-adequacy-of-price-and-process-in-proposed-sale-of-kalvista-pharmaceuticals-inc-kalv\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/kalvista-pharmaceuticals-investor-alert-kahn-swick-foti-llc-investigates-adequacy-of-price-and-process-in-proposed-sale-of-kalvista-pharmaceuticals-inc-kalv\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kalvista-pharmaceuticals-investor-alert-kahn-swick-foti-llc-investigates-adequacy-of-price-and-process-in-proposed-sale-of-kalvista-pharmaceuticals-inc-kalv\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260501487041r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260501487041r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kalvista-pharmaceuticals-investor-alert-kahn-swick-foti-llc-investigates-adequacy-of-price-and-process-in-proposed-sale-of-kalvista-pharmaceuticals-inc-kalv\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"KalVista Pharmaceuticals Investor Alert: Kahn Swick &amp; Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of KalVista Pharmaceuticals, Inc. &#8211; KALV"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/957243","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=957243"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/957243\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=957243"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=957243"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=957243"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}